PARTHENOLIDE: SUGGESTED DRUG FOR COVID-19

被引:0
|
作者
Nemati, M. [1 ]
Pouya, F. Danesh [1 ]
Asl, E. Roshni [1 ]
Rasmi, Y. [1 ,2 ]
机构
[1] Urmia Univ Med Sci, Dept Biochem, Sch Med, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Cellular & Mol Res Ctr, Orumiyeh, Iran
来源
INFEKTSIYA I IMMUNITET | 2020年 / 10卷 / 04期
关键词
Parthenolide; COVID-19; NF-kappa B; ACTIVATION; INHIBITORS;
D O I
10.15789/2220-7619-PSD-1509
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Parthenolide is a sesquiterpene lactone found in medicinal plants. It can inhibit several pro-inflammatory signaling pathways, in particular the ATPase activity of NLRP3. Based on its ability to suppress inflammatory signal transduction and elevated level of serum IL-1 beta (a surrogate marker for NLRP3 activation) in COVID-19 patients, we suggest that PN could be potentiallyeffective for the treatment of COVID-19.
引用
收藏
页码:789 / 791
页数:3
相关论文
共 50 条
  • [41] Teicoplanin: an alternative drug for the treatment of COVID-19?
    Baron, Sophie Alexandra
    Devaux, Christian
    Colson, Philippe
    Raoult, Didier
    Rolain, Jean-Marc
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (04)
  • [42] Explosive drug information in the time of COVID-19
    Schulz, Martin
    Schumacher, Pia M.
    Schneider, Juliana
    Said, Andre
    Laufs, Ulrich
    CANADIAN PHARMACISTS JOURNAL, 2021, 154 (04) : 232 - 233
  • [43] Drug Shortages Amid the COVID-19 Pandemic
    Bookwalter, Christina M.
    US PHARMACIST, 2021, 46 (02) : 25 - 28
  • [44] Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?
    Devaux, Christian A.
    Melenotte, Clea
    Piercecchi-Marti, Marie-Dominique
    Delteil, Clemence
    Raoult, Didier
    FRONTIERS IN MEDICINE, 2021, 8
  • [45] Editorial: Drug Repurposing for COVID-19 Therapy
    Maldonado, Rafael
    Drago, Filippo
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [46] COVID-19 drug studies get boost
    Brainard, Jeffrey
    SCIENCE, 2021, 372 (6549) : 1372 - 1372
  • [47] A review on drug repurposing applicable to COVID-19
    Dotolo, Serena
    Marabotti, Anna
    Facchiano, Angelo
    Tagliaferri, Roberto
    BRIEFINGS IN BIOINFORMATICS, 2021, 22 (02) : 726 - 741
  • [48] COVID-19: ANALYSIS OF DRUG REPOSITIONING PRACTICE
    Savosina, P. I.
    Druzhilovskii, D. S.
    Poroikov, V. V.
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2021, 54 (10) : 989 - 996
  • [49] COVID-19 and hydroxychloroquine: Is the wonder drug failing?
    Paliani, Ugo
    Cardona, Andrea
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 78 : 1 - 3
  • [50] Drug repurposing approach to fight COVID-19
    Singh, Thakur Uttam
    Parida, Subhashree
    Lingaraju, Madhu Cholenahalli
    Kesavan, Manickam
    Kumar, Dinesh
    Singh, Raj Kumar
    PHARMACOLOGICAL REPORTS, 2020, 72 (06) : 1479 - 1508